Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, will be hosting next month’s DMT Conference. Held in an entirely virtual format, the conference is slated for Sept. 9–10, 2021. According to the announcement, the event will focus on the potential of dimethyltryptamine (“DMT”) regarding drug development and safety, clinical care, law and regulation, business and markets, science and research. The DMT conference is part of Microdose’s Molecular Masterclasses conference events, a speaker series designed for deep dives into the world’s favorite psychoactive and psychedelic substances. The informative DMT Conference is designed to provide insight and education into the space of DMT therapeutics and will feature expert panels and engaging discussions. The 2021 conference will feature a presentation by CEO of Microdose Psychedelic Insights Patrick Moher as well as a series of hourlong presentations and various keynote addresses. Topics to be covered will include “Addiction and DMT,” “Non-Neuropsychiatric Uses for DMT,” “DMT Drug Development,” and a keynote presentation by Algernon Pharmaceuticals titled “DMT — New Hope for Healing the Brain After a Stroke,” among others. Conference presenters include Christopher Timmermann-Slater, Andrew Hegle, Paul Van Slyke, Daniel Cohen, Christopher Moreau, Jackie von Salm, Carol Routledge, Brian Jahns, Natan Ponieman, Andrew Hegle Paul Van Slyke, Peter Rands, Graham Pechenik, David Wood, Ruth Chun, Hadas Alterman, Rick Strassman, Timothy Ko, Brian Jahns, Crystal Carson, Joël Brierre, Max Montrose, Tricia Eastman, Rak Razam, and Victoria Wueschner among others.
To attend the full conference, visit https://ibn.fm/7TbOg
To view the full press release, visit https://ibn.fm/MNUgQ
About Microdose Psychedelic Insights
Microdose Psychedelic Insights is a guide to the psychedelic medicine industry. With a vision to shift the world’s perception of psychedelic medicine, the company distribute and create the most compelling content, financial analysis, engaging events, and ground-breaking education to drive the psychedelics industry to the forefront of modern medicine. For more information about the company, visit www.Microdose.buzz.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.